Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced a partnership with Central Admixture Pharmacy Services (CAPS). The agreement will allow BD Intelliport Medication Management System customers to buy a portfolio of frequently used CAPS' pre-filled anesthesia syringes.
According to BD, “CAPS’ pre-filled anesthesia syringes are designed to prevent common compounding and labeling errors that occur in the operating room. These syringes are prepared in a controlled environment and undergo continuous testing for sterility, potency and endotoxin to meet strict new FDA quality control requirements.”
BD’s Intelliport System can automatically identify and utilize these syringes. The system is capable of providing real-time medication identification, dose measurement and patient drug allergy alerts at the point of injection. It is also capable of updating patient's electronic medical record (EMR) following medication administration.
The new collaboration reflects BD’s growing focus on patient safety and improving workflow. The earlier announced collaborations with Medtronic (MDT - Free Report) -- for the infusion set and Parker Institute for Cancer Immunotherapy -- in relation to the new Cell Sorter program are key growth drivers in our view.
Apart from partnerships, BD’s endeavor to develop innovative products is noteworthy. A plethora of FDA approvals in recent times has added products like Totalys MultiProcessor and Totalys SlidePrep instruments, FACSPresto system and FACSPresto CD4/Hb Cartridge and Vacutainer UltraTouch Push Button Blood Collection Set to the company’s portfolio.
Recently, BD announced the receipt of CE marking for its BD MAX Vaginal Panel -- a new in-vitro diagnostic (IVD) assay. The product expands BD’s reproductive and sexually transmitted Infections Portfolio.
Most recently, BD introduced its newest cell sorter -- the BD FACSMelody system -- which follows the launch of the company’s flow cytometers like BD Accuri C6 Plus and BD FACSCelesta systems.
Zacks Rank & Key Picks
BD carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the same space include Halyard Health and C.R. Bard . While Halyard Health sports a Zacks Rank #1 (Strong Buy), C.R. Bard has a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced a partnership with Central Admixture Pharmacy Services (CAPS). The agreement will allow BD Intelliport Medication Management System customers to buy a portfolio of frequently used CAPS' pre-filled anesthesia syringes.
According to BD, “CAPS’ pre-filled anesthesia syringes are designed to prevent common compounding and labeling errors that occur in the operating room. These syringes are prepared in a controlled environment and undergo continuous testing for sterility, potency and endotoxin to meet strict new FDA quality control requirements.”
BD’s Intelliport System can automatically identify and utilize these syringes. The system is capable of providing real-time medication identification, dose measurement and patient drug allergy alerts at the point of injection. It is also capable of updating patient's electronic medical record (EMR) following medication administration.
The new collaboration reflects BD’s growing focus on patient safety and improving workflow. The earlier announced collaborations with Medtronic (MDT - Free Report) -- for the infusion set and Parker Institute for Cancer Immunotherapy -- in relation to the new Cell Sorter program are key growth drivers in our view.
Apart from partnerships, BD’s endeavor to develop innovative products is noteworthy. A plethora of FDA approvals in recent times has added products like Totalys MultiProcessor and Totalys SlidePrep instruments, FACSPresto system and FACSPresto CD4/Hb Cartridge and Vacutainer UltraTouch Push Button Blood Collection Set to the company’s portfolio.
Recently, BD announced the receipt of CE marking for its BD MAX Vaginal Panel -- a new in-vitro diagnostic (IVD) assay. The product expands BD’s reproductive and sexually transmitted Infections Portfolio.
Most recently, BD introduced its newest cell sorter -- the BD FACSMelody system -- which follows the launch of the company’s flow cytometers like BD Accuri C6 Plus and BD FACSCelesta systems.
Zacks Rank & Key Picks
BD carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the same space include Halyard Health and C.R. Bard . While Halyard Health sports a Zacks Rank #1 (Strong Buy), C.R. Bard has a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BDX - FREE
Get the latest research report on MDT - FREE